Aktis Oncology financials
$19.69+1.76%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY24 Jun 30 | FY23 Jun 30 | FY22 Jun 30 | FY21 Jun 30 | FY20 Jun 30 | FY19 Jun 30 | FY18 Jun 30 | FY17 Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $27.4M | $27.1M | $15.3M | $6.6M | $1.8M | $1.4M | $1.2M | $486.5K |
| Gross profit | -$689.0K | -$3.1M | -$4.1M | -$4.0M | -$624.0K | $430.0K | $188.0K | $486.5K |
| Gross margin | −2.5% | −11.5% | −27.0% | −60.9% | −34.9% | 29.8% | 15.6% | 100.0% |
| Operating income | -$110.0M | -$66.1M | -$60.6M | -$46.5M | -$32.0M | -$27.6M | -$22.2M | -$10.7M |
| Net income | -$167.9M | -$63.6M | -$59.0M | -$44.2M | -$36.1M | -$29.2M | -$21.7M | -$9.8M |
| Net margin | −613.3% | −234.3% | −384.5% | −667.2% | −2019.0% | −2026.9% | −1799.6% | −2021.2% |
| Diluted EPS | $-1.89 | $-1.00 | $-1.09 | $-1.02 | $-1.07 | $-1.06 | $-1.04 | $-0.58 |
| EBITDA | -$53.8M | -$54.8M | -$52.4M | -$41.6M | -$28.9M | -$25.1M | -$20.6M | -$10.6M |
| Operating cash flow | -$40.3M | -$44.8M | -$45.2M | -$29.4M | -$21.3M | -$17.7M | -$14.2M | -$5.5M |
| Free cash flow | -$46.3M | -$56.2M | -$72.9M | -$41.8M | -$31.1M | -$22.4M | -$21.1M | -$10.0M |
| Diluted shares | 89.1M | 63.6M | 54.0M | 43.4M | 33.7M | 27.5M | 20.9M | 17.0M |
Balance sheet
| Period end | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $24.4M | $43.1M | $80.5M | $88.3M | $44.3M | $30.1M |
| Short-term investments | $0.00 | $0.00 | — | — | — | — |
| Total debt | $51.9M | $43.3M | $117.0K | $117.0K | $23.3M | $18.3M |
| Total assets | $69.7M | $148.9M | $161.3M | $125.0M | $71.4M | $47.9M |
| Total liabilities | $126.8M | $62.7M | $57.9M | $7.6M | $29.9M | $22.0M |
| Shareholders' equity | -$57.1M | $86.2M | $103.4M | $117.4M | $41.5M | $26.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology